COVID-19 Infection vs Vaccination and the Risk of New-onset Psoriasis

Read full text
Authors: Sophie L. Preuß, Henning Olbrich, Katja Bieber, Artem Vorobyev, Eva Lotta Moderegger, Khalaf Kridin, Henner Zirpel, Diamant Thaçi, Evelyn Gaffal, R. Ludwig, Philip Curman
Cited by: 1
References: 36

Abstract

Emerging evidence has suggested a link between new-onset psoriasis and both COVID-19 infection and vaccination, though findings have been limited by small case numbers and lack of adequate control groups. This retrospective cohort study used electronic health records from the US Collaborative Network of TriNetX from January 2020 to January 2025 to compare the risk of developing new-onset psoriasis in individuals with confirmed COVID-19 infection and no vaccination history vs those vaccinated without prior infection. Propensity score matching was applied to balance demographics, comorbidities, and psoriasis risk factors. The primary outcome was a new diagnosis of psoriasis (ICD10-CM: L40.0-5) within 3 months following infection or vaccination. Subgroup analyses assessed the specific codes L40.0-5 separately. Kaplan-Meier survival analysis and Cox proportional hazards models were used to compare outcomes. Patients with COVID-19 infection had a significantly higher risk of developing psoriasis compared with vaccinated individuals (HR 1.30; 95% CI, 1.14-1.49; p < 0.001). Increased risks were also observed for psoriatic arthritis and pustulosis palmaris et plantaris. These findings suggest a potential triggering role of infection in psoriasis pathogenesis and support the safety profile of vaccination. Further studies are needed to confirm causality and guide clinical decision-making.

Fields of Study & Subjects

Psoriasis: Treatment and Pathogenesis Spondyloarthritis Studies and Treatments Dermatological and COVID-19 studies

Publication details

Journal / source
Acta Dermato Venereologica
Publisher
MJS Publishing, Medical Journals Sweden AB
Volume
106
Pages
adv44217–adv44217
Publication date
8 January 2026
Language
EN